Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.

CPE-003 · synthetic case CKD-EX-13

Metformin in the eGFR 30–44 review zone

eGFR 38 on metformin.

Synthetic · no real patientExtended demonstration caseKidney engine v1.2.0

Purpose: eGFR 38 on metformin.

Inputs the engine received

Patient

Age
71 years

Context

Sex for equation
female
Medication active
metformin

Laboratory

eGFR selected
38 mL/min/1.73 m²

What the engine reports

Detected clinical pattern

Kidney Abnormality Detected — CKD Not Confirmed

A single abnormal result does not establish CKD. Persistence over at least three months and exclusion of acute or transient causes are needed.

  • Chronicity: Chronicity unconfirmed
  • CGA: Indicative G3bA? (not a classification)

Clinical summary

A kidney abnormality was detected (eGFR 38), but chronicity is not established; CKD is not confirmed. Priority: confirm persistence and exclude acute or transient causes.

Why this pattern was identified

  • Estimated GFR. 38 mL/min/1.73 m² (externally reported), category G3b (30–44).

Calculations

eGFR (externally reported)
38 mL/min/1.73 m²

Recommended next steps

For physician consideration. Urgent review always comes first.

  1. 1Confirm persistence (repeat testing at ≥3 months) and evaluate acute or transient causes before labeling CKD.A single abnormal eGFR or UACR does not establish CKD.

Missing information

  • UACR (required for the A category, risk assessment and a complete classification).

Why it matters

Isolated abnormal eGFR or UACR values are common and often transient. Labeling CKD early can misclassify patients, while missing persistent disease delays care. Confirmation at three months balances both.

Evidence and rule trace · 3 rules

DET-001Kidney abnormality detected

Inputs: eGFR 38 (<60)

kidney_abnormality_detected: determine chronicity and evaluate acute causes before confirming CKD

CHR-003Single abnormal result does not confirm CKD

Inputs: abnormality without dated evidence of ≥3 months

kidney_abnormality_unconfirmed: CKD is not confirmed

MED-MET-002Metformin initiation/continuation review zone

Inputs: eGFR 38 (30–44) · metformin active or proposed

Do not initiate in the eGFR 30–45 range per labeling; if already taking, assess benefit–risk of continuing. Verify current product labeling.

Evidence

  • R1 · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.
  • R8 · GLUCOPHAGE / GLUCOPHAGE XR Prescribing Information - Renal Impairment Recommendations. U.S. Food and Drug Administration (FDA) - Drugs@FDA labeling, 2017.

Physician adjudication required. Clinical decision support for physician review. Criteria-based status is not a probability. Findings require physician adjudication and correlation with the complete clinical context. Validation-only release: not for production clinical use.

Change the values

The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.

Live eGFR and CGA map

eGFR (mL/min/1.73 m²)

38

externally reported

GFR \ ALBA1<30A230–300A3>300
G1≥90
G260–89
G3a45–59
G3b30–44
G415–29
G5<15

Indicative cell G3bA? only: CKD is not confirmed, so this is not a classification. Colors follow the KDIGO risk heat map: green low, yellow moderately increased, orange high, red very high.

Kidney functionAdd a prior result with dates to test chronicity
Sex for the equation

Switches the engine to the combined eGFRcr-cys equation.

Albuminuria
Chemistry
Kidney findings and red flags
Context
Transient albuminuria confounders
Creatinine may be unreliable
Complications (persistent)
Therapy
Documented history and special populations

This case also carries values that have no field here: eGFR_selected. They are included in the calculation until you clear the form.

Live result · computed in your browser

Detected clinical pattern

Kidney Abnormality Detected — CKD Not Confirmed

A single abnormal result does not establish CKD. Persistence over at least three months and exclusion of acute or transient causes are needed.

  • Chronicity: Chronicity unconfirmed
  • CGA: Indicative G3bA? (not a classification)

Clinical summary

A kidney abnormality was detected (eGFR 38), but chronicity is not established; CKD is not confirmed. Priority: confirm persistence and exclude acute or transient causes.

Why this pattern was identified

  • Estimated GFR. 38 mL/min/1.73 m² (externally reported), category G3b (30–44).

Calculations

eGFR (externally reported)
38 mL/min/1.73 m²

Recommended next steps

For physician consideration. Urgent review always comes first.

  1. 1Confirm persistence (repeat testing at ≥3 months) and evaluate acute or transient causes before labeling CKD.A single abnormal eGFR or UACR does not establish CKD.

Missing information

  • UACR (required for the A category, risk assessment and a complete classification).

Why it matters

Isolated abnormal eGFR or UACR values are common and often transient. Labeling CKD early can misclassify patients, while missing persistent disease delays care. Confirmation at three months balances both.

Evidence and rule trace · 3 rules

DET-001Kidney abnormality detected

Inputs: eGFR 38 (<60)

kidney_abnormality_detected: determine chronicity and evaluate acute causes before confirming CKD

CHR-003Single abnormal result does not confirm CKD

Inputs: abnormality without dated evidence of ≥3 months

kidney_abnormality_unconfirmed: CKD is not confirmed

MED-MET-002Metformin initiation/continuation review zone

Inputs: eGFR 38 (30–44) · metformin active or proposed

Do not initiate in the eGFR 30–45 range per labeling; if already taking, assess benefit–risk of continuing. Verify current product labeling.

Evidence

  • R1 · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.
  • R8 · GLUCOPHAGE / GLUCOPHAGE XR Prescribing Information - Renal Impairment Recommendations. U.S. Food and Drug Administration (FDA) - Drugs@FDA labeling, 2017.

Physician adjudication required. Clinical decision support for physician review. Criteria-based status is not a probability. Findings require physician adjudication and correlation with the complete clinical context. Validation-only release: not for production clinical use.

More kidney cases

All kidney cases

The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.

Contact Biod